Selecta Biosciences (SELB) Misses Q4 EPS by 2c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. GOOGL
2. ENPH
3. NOW
4. HOOD
5. BA
6. STX
7. NXPI
8. SPY
9. MSFT
10. CSGP

Go back to Selecta Biosciences (SELB) Misses Q4 EPS by 2c, Revenues Beat

Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

March 11, 2021 8:00 AM EST

- First-in-human dose-escalation study to evaluate ability of ImmTOR to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 -

- Methylmalonic acidemia (MMA) gene therapy program in collaboration with AskBio expected to enter the clinic in the second quarter of 2021 -

- Pediatric Investigation Plan (PIP) for ornithine transcarbamylase (OTC) deficiency gene therapy program submitted to the EMA pediatric committee -

- Investigational New Drug (IND) application for IgA... More